From openly blocking models for relevant pharma problems, to silently reducing Fable capabilities for frontier AI research, to now fully blocking the use of Fable, the signal is clear.
There has never been a more relevant and exciting time to be building in the open, right at the critical intersection of AI and drug development. This is where incentivised open science will lead.
#
Bittensor#